Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.44 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 17/20 | 0.75 |
| ▸ | KDR | P35968 | 8/20 | 0.75 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.75 |
| ▸ | TEK | Q02763 | 2/20 | 0.75 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.75 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.75 |
| ▸ | RET | P07949 | 3/20 | 0.59 |
| ▸ | FLT3 | P36888 | 3/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | LCK | P06239 | 2/20 | 0.59 |
| ▸ | LYN | P07948 | 2/20 | 0.59 |
| ▸ | HCK | P08631 | 2/20 | 0.59 |
| ▸ | BCR | P11274 | 2/20 | 0.59 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.59 |
| ▸ | ABL2 | P42684 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1728382 | 0.99 | MET (0.76) | METKDRNTRK1TEKNTRK3 | |
| Hydrochloric Acid SCHEMBL1728468 | 0.98 | MET (0.75) | METKDRNTRK1TEKNTRK3 | |
| Sulfuric Acid SCHEMBL5133938 | 0.96 | MET (0.72) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL1727515 | 0.95 | MET (0.71) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL1728634 | 0.93 | MET (0.68) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2253535 | 0.93 | MET (0.74) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2252601 | 0.93 | MET (0.74) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL3061676 | 0.93 | MET (0.74) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL4250644 | 0.91 | MET (0.65) | METKDRNTRK1TEKNTRK3 | |
| SCHEMBL2251712 | 0.91 | MET (0.77) | METKDRNTRK1TEKNTRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377938-B2 | Phenoxypyridine derivative salts and crystals thereof, and process for preparing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-02-19 | — | — | US | disclosed |
| EP-2062886-A1 | SALT OF PHENOXYPYRIDINE DERIVATIVE OR CRYSTAL THEREOF AND PROCESS FOR PRODUCING THE SAME | Eisai R&D Management Co., Ltd. (JP) | 2009-05-27 | — | — | EP | disclosed |
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | EISAI R&D MANAGEMENT CO., LTD (JP) | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318924-A1 | PHENOXYPYRIDINE DERIVATIVE SALTS AND CRYSTALS THEREOF, AND PROCESS FOR PREPARING THE SAME | HGF, MET, FLT1 | CHRM2 4420/4885ADRA2A 2427/4885ADRA2C 2500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.